We demonstrated that DCK and CCNL1 contribute to gemcitabine resistance in pancreatic cancer by performing genome-wide CRISPR/Cas9 knockout screening in the mouse pancreatic cancer cell line TB32047 under gemcitabine treatment. This evidence concerns the gene DCK and familial pancreatic carcinoma.